Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00965003
Other study ID # ENT0019
Secondary ID 96536SU-05292009
Status Terminated
Phase Early Phase 1
First received August 21, 2009
Last updated October 3, 2017
Start date July 2009
Est. completion date January 2010

Study information

Verified date October 2017
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To determine if high resolution MRI can detect early invasion of cartilage by laryngeal carcinoma, and to determine if high resolution MRI may be superior to conventional MRI imaging or CT imaging to detect cartilage invasion.


Description:

The purpose of this study is to use a new MRI imaging coil developed for enhancing structures made of cartilage to determine if the device can produce improved images of the human larynx. In addition, if enhanced images can be obtained, a further purpose will be to determine if, in patients with laryngeal cancer, whether or not early invasion of cartilage can be detected. Patients with laryngeal cancer will be asked to undergone an MRI scan using this new image-enhancing coil to see if cartilage invasion can be detected. Patients will be followed during and after treatment to determine their ultimate response to treatment. No additional MRI scans for the purposes of this protocol will be performed other than the initial pretreatment scan.

We hope to determine if this new MRI imaging device can detect early cancer invasion of the laryngeal cartilages in patients with laryngeal cancer. Since this modality has never been attempted before on the human larynx, we are simply looking for the presence or absence of cartilage destruction. Both conventional CT and conventional MRI are poor at recongnizing this finding. High resolution MRI may allow the detection of this finding or it may not - detection of this finding is the endpoint.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date January 2010
Est. primary completion date January 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with benign or malignant neoplasm of the larynx.

- Patients who have undergone prior surgery, radiation therapy, or chemotherapy for cancer of the laryngopharynx will be eligible to participate.

- Patients 18 years of age and older at time of evaluation, male and female, all ethnicities.

- Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

- Pregnancy

- Claustrophobia.

- Anatomic parameters which preclude scanning, such as limited range of neck motion, or inability to remain flat for at least 15 minutes.

- Patients with implanted devices (eg, defibrillator, pacemaker) that are a known contraindication to magnetic resonance imaging.

- Allergy to gadolinium contrast.

Study Design


Intervention

Procedure:
MRI scan
Standard of Care

Locations

Country Name City State
United States Stanford University School of Medicine Stanford California

Sponsors (1)

Lead Sponsor Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tumor stage as determined by HRMRI. Radiologic tumor stage 24 to 48 hours
Secondary Estimate the precision of HRMRI in discriminating between edema and tumor in patients with prior radiotherapy or chemotherapy. Comparison of true tumor dimension as predicted by HRMRI versus true tumor size as shown on final histopathology 4 to 6 weeks
Secondary Tumor stage as determined by histopathology in excised larynges. Pathological tumor stage 4 to 6 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06016699 - Immunological Function After Radiation With Either Proton or Photon Therapy
Completed NCT03292341 - Evaluation of a Web-based Decision Aid Tool for Larynx Cancer (T3/T4) Patients. N/A
Completed NCT03653039 - Comparison Between a Standard Tube and the Ultra-thin Tritube for Intubation of the Trachea and for Maintaining Access to the Trachea After Anaesthesia, in Patients With an Expected Difficult Direct Laryngoscopy N/A
Completed NCT05746780 - Bilateral Elective Neck Dissection in Salvage Total Laryngectomy
Recruiting NCT05793151 - Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy N/A
Completed NCT01700647 - Breath Testing in Early and Late Larynx Cancer N/A
Completed NCT00600223 - Functional Voice and Speech Outcomes Following Surgical Voice Restorations: A Comparison of Pharyngeal Construction Approaches N/A
Completed NCT00169247 - Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation Phase 2
Recruiting NCT03759431 - Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer Phase 2
Active, not recruiting NCT02586207 - Pembrolizumab in Combination With CRT for LA-SCCHN Phase 1
Recruiting NCT04057209 - VoiceS: Voice Quality After Transoral CO2-Laser Surgery Versus Single Vocal Cord Irradiation for Larynx Cancer N/A
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting NCT06086119 - Quality of Life and Voice Perception in Patients Laryngoctomized Phonatory Wearers
Suspended NCT04368702 - CONFIRM: Magnetic Resonance Guided Radiation Therapy N/A
Completed NCT05217147 - An Investigation of Biomarker Candidate Molecules in Laryngeal Carcinoma
Active, not recruiting NCT03082534 - Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Phase 2
Completed NCT00158652 - Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Phase 3
Terminated NCT03479463 - Use of Human Dehydrated Amnion Chorion Allograft in Laryngectomy/Pharyngectomy
Completed NCT03096808 - Adaptive Radiotherapy for Head and Neck Cancer Phase 2
Completed NCT03028766 - WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer Phase 1